Key result
SGLT2 inhibitors may improve contractile bioenergetics and reduce cardiovascular mortality and heart failure hospitalizations by inducing changes in cardiac metabolism.
Why the study?
SGLT2 inhibitors reduce cardiovascular mortality and heart failure hospitalizations, but the mechanisms underlying these benefits remain uncertain.
SGLT2 inhibitors may improve contractile bioenergetics and exert anti-inflammatory properties, supporting their use as an alternative drug to treat heart failure patients regardless of diabetic status.
No takes yet. Share an insight, caveat, or question.
Reported metabolic shifts may underlie SGLT2i HF benefits; extends mechanistic insights but leaves open causal validation.
García‐Ropero et al. (2019) conducted a review in Heart failure. SGLT2 inhibitors was evaluated. SGLT2 inhibitors may improve contractile bioenergetics and reduce cardiovascular mortality and heart failure hospitalizations by inducing changes in cardiac metabolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: